This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol 2012;50:458–70. doi: 10.3109/15563650.2012.702218SchepLJKnudsenKSlaughterRJValeJAMégarbaneBThe clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediolClin Toxicol2012504587010.3109/15563650.2012.702218Open DOISearch in Google Scholar
Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem® Differences in characteristics and misuse. Drug Alcohol Depend 2009;104:1–10. doi: 10.1016/J. DRUGALCDEP.2009.04.012CarterLPPardiDGorslineJGriffithsRRIllicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem® Differences in characteristics and misuseDrug Alcohol Depend200910411010.1016/J.DRUGALCDEP.2009.04.012Open DOISearch in Google Scholar
Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001;63:1–22. doi: 10.1016/ S0376-8716(00)00191-5NicholsonKLBalsterRLGHB: a new and novel drug of abuseDrug Alcohol Depend20016312210.1016/S0376-8716(00)00191-5Open DOISearch in Google Scholar
Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome. Eur Rev Med Pharmacol Sci 2015;19:4654–63. PMID: 26698265BusardòFPKyriakouCNapoletanoSMarinelliEZaamiSClinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndromeEur Rev Med Pharmacol Sci201519465463PMID: 26698265Search in Google Scholar
Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011;3:417–25. doi: 10.1002/dta.292WoodDMBrailsfordADDarganPIAcute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD)Drug Test Anal201134172510.1002/dta.29221548140Open DOISearch in Google Scholar
Rambourg-Schepens MO, Buffet M, Durak C, Mathieu-Nolf M. Gamma butyrolactone poisoning and its similarities to gamma hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997;39:234–5. PMID: 9251175Rambourg-SchepensMOBuffetMDurakCMathieu-NolfMGamma butyrolactone poisoning and its similarities to gamma hydroxybutyric acid: two case reportsVet Hum Toxicol1997392345PMID: 9251175Search in Google Scholar
Busardò FP, Gottardi M, Tini A, Minutillo A, Sirignano A, Marinelli E, Zaami S. Replacing GHB with GBL in recreational settings: a new trend in chemsex. Curr Drug Metab 2018;19:1080–5. doi: 10.2174/13892002196661809 25090834BusardòFPGottardiMTiniAMinutilloASirignanoAMarinelliEZaamiSReplacing GHB with GBL in recreational settings: a new trend in chemsexCurr Drug Metab2018191080510.2174/138920021966618092509083430251602Open DOISearch in Google Scholar
Hibell B, Andersson B, Bjarnason T, Ahlström S, Balakireva O, Kokkevi A, Morgan M. The ESPAD report 2003 : alcohol and other drug use among students in 35 European countries. Stockholm: Swedish Council for Information on Alcohol and Other Drugs (CAN); 2004.HibellBAnderssonBBjarnasonTAhlströmSBalakirevaOKokkeviAMorganMThe ESPAD report 2003 : alcohol and other drug use among students in 35 European countriesStockholmSwedish Council for Information on Alcohol and Other Drugs (CAN)2004Search in Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of GHB in the Framework of the Joint Action on New Synthetic Drugs. Luxembourg: Office for Official Publications of the European Communities; 2002.European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of GHB in the Framework of the Joint Action on New Synthetic DrugsLuxembourgOffice for Official Publications of the European Communities;2002Search in Google Scholar
Knudsen K, Greter J, Verdicchio M. High mortality rates among GHB abusers in Western Sweden. Clin Toxicol 2008;46:187–92. doi: 10.1080/15563650701263633KnudsenKGreterJVerdicchioMHigh mortality rates among GHB abusers in Western SwedenClin Toxicol2008461879210.1080/1556365070126363318344100Open DOISearch in Google Scholar
Wood DM, Nicolaou M, Dargan PI. Epidemiology of Recreational Drug Toxicity in a Nightclub Environment. Subst Use Misuse 2009;44:1495–502. doi: 10.1080/10826080802543580WoodDMNicolaouMDarganPIEpidemiology of Recreational Drug Toxicity in a Nightclub EnvironmentSubst Use Misuse200944149550210.1080/1082608080254358019938928Open DOISearch in Google Scholar
Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardò FP. When “chems” meet sex: a rising phenomenon called “chemsex”. Curr Neuropharmacol 2017;15:762–70. doi: 10.2174/1570159X15666161117151148GiorgettiRTagliabracciASchifanoFZaamiSMarinelliEBusardòFPWhen “chems” meet sex: a rising phenomenon called “chemsex”Curr Neuropharmacol2017157627010.2174/1570159X15666161117151148577105227855594Open DOISearch in Google Scholar
Marinelli S, Berretta P, Pacifici R, Del Rio A. Sex enhancers: challenges, threats and the need for targeted measures. Clin Ter 2019;170(3):e181–3. doi: 10.7417/CT.2019.2130MarinelliSBerrettaPPacificiRDelRio ASex enhancers: challenges, threats and the need for targeted measuresClin Ter20191703e181310.7417/CT.2019.213031173047Open DOISearch in Google Scholar
Zaami S, Giorgetti R, Pichini S, Pantano F, Marinelli E, Busardò FP. Synthetic cathinones related fatalities: an update. Eur Rev Med Pharmacol Sci 2018;22:268–74. doi: 10.26355/eurrev_201801_14129ZaamiSGiorgettiRPichiniSPantanoFMarinelliEBusardòFPSynthetic cathinones related fatalities: an updateEur Rev Med Pharmacol Sci2018222687410.26355/eurrev_201801_1412929364498Open DOISearch in Google Scholar
Gentili S, Mortali C, Mastrobattista L, Berretta P, Zaami S. Determination of different recreational drugs in sweat by headspace solid-phase microextraction gas chromatography mass spectrometry (HS-SPME GC/MS): Application to drugged drivers. J Pharm Biomed Anal 2016;129:282–7. doi: 10.1016/j.jpba.2016.07.018GentiliSMortaliCMastrobattistaLBerrettaPZaamiSDetermination of different recreational drugs in sweat by headspace solid-phase microextraction gas chromatography mass spectrometry (HS-SPME GC/MS): Application to drugged driversJ Pharm Biomed Anal2016129282710.1016/j.jpba.2016.07.01827442890Open DOISearch in Google Scholar
Gamma Hydroxy Butyrate Usage, Effects and UK Prices [displayed 10 July 2019]. Available at http://www.idmu.co.uk/oldsite/ghb.htmGamma Hydroxy Butyrate Usage, Effects and UK Prices[displayed 10 July2019Available athttp://www.idmu.co.uk/oldsite/ghb.htmSearch in Google Scholar
McCambridge J, Mitcheson L, Winstock A, Hunt N. Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom. Addiction 2005;100:1140–9. doi: 10.1111/j.1360-0443.2005.01127.xMcCambridgeJMitchesonLWinstockAHuntNFive-year trends in patterns of drug use among people who use stimulants in dance contexts in the United KingdomAddiction 2005;100:1140–910.1111/j.1360-0443.2005.01127.xOpen DOISearch in Google Scholar
Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use. Overview of Key Findings, 2011. Ann Arbor (MI): Institute for Social Research The University of Michigan; 2012.JohnstonLDO’MalleyPMBachmanJGSchulenbergJEMonitoring the Future National Results on Adolescent Drug Use. Overview of Key Findings, 2011Ann Arbor (MI)Institute for Social Research The University of Michigan;2012Search in Google Scholar
Busardò FP, Bertol E, Vaiano F, Baglio G, Montana A, Barbera N, Zaami S, Romano G. Post mortem concentrations of endogenous gamma hydroxybutyric acid (GHB) and in vitro formation in stored blood and urine samples. Forensic Sci Int 2014;243:144–8. doi: 10.1016/j.forsciint.2014.07.019BusardòFPBertolEVaianoFBaglioGMontanaABarberaNZaamiSRomanoGPost mortem concentrations of endogenous gamma hydroxybutyric acid (GHB) and in vitro formation in stored blood and urine samplesForensic Sci Int2014243144810.1016/j.forsciint.2014.07.01925123534Open DOISearch in Google Scholar
Marchei E, Tini A, Pirani F, Lo Faro AF, Marinelli S. Is GHB-glucuronide useful as a biomarker for the exogenous use of GHB? Eur Rev Med Pharmacol Sci 2019;23:2311–3. doi: 10.26355/eurrev_201903_17369MarcheiETiniAPiraniFLoFaro AFMarinelliSIs GHB-glucuronide useful as a biomarker for the exogenous use of GHB? Eur Rev Med Pharmacol Sci2019232311310.26355/eurrev_201903_1736930964152Open DOISearch in Google Scholar
Solimini R, Rotolo MC, Pellegrini M, Minutillo A, Pacifici R, Busardò FP, Zaami S. Adulteration practices of psychoactive illicit drugs: an updated review. Curr Pharm Biotechnol 2017;18:524–30. doi: 10.2174/1389201018666 170710184531SoliminiRRotoloMCPellegriniMMinutilloAPacificiRBusardòFPZaamiSAdulteration practices of psychoactive illicit drugs: an updated reviewCurr Pharm Biotechnol2017185243010.2174/138920101866617071018453128699480Open DOISearch in Google Scholar
Pichini S, Marchei E, Pacifici R, Marinelli E, Busardò FP. Chemsex intoxication involving sildenafil as an adulterant of GHB. Drug Test Anal 2017;9:956–9. doi: 10.1002/dta.2054PichiniSMarcheiEPacificiRMarinelliEBusardòFPChemsex intoxication involving sildenafil as an adulterant of GHBDrug Test Anal20179956910.1002/dta.205427527498Open DOISearch in Google Scholar
Busardo FP, Kyriakou C. GHB in biological specimens: which cut-off levels should be taken into consideration in forensic toxicological investigation? Recent Pat Biotechnol 2014;8:206–14. doi: 10.2174/1872208309666150504143155BusardoFPKyriakouCGHB in biological specimens: which cut-off levels should be taken into consideration in forensic toxicological investigation? Recent Pat Biotechnol201482061410.2174/187220830966615050414315527099144Open DOISearch in Google Scholar
Beck R, Matanović SM, Zibar L. Gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol addiction: a serious health threat. Arh Hig Rada Toksikol 2019;70:149–50. doi: 10.2478/aiht-2019-70-3295BeckRMatanovićSMZibarLGamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol addiction: a serious health threatArh Hig Rada Toksikol2019701495010.2478/aiht-2019-70-329531246568Open DOISearch in Google Scholar
Laborit H, Jouany JM, Gerard J, Fabiani F. [Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate, in French]. Presse Med 1960;68:1867–9. PMID: 13758012LaboritHJouanyJMGerardJFabianiF[Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate, in French]Presse Med19606818679PMID: 13758012Search in Google Scholar
Zaytseff A. Über die Reduction des Succinylchlorids [On the reduction of succinyl chloride, in German]. Justus Liebigs Ann Chem 1874;171:258–90. doi:10.1002/jlac.18741710216ZaytseffAÜber die Reduction des Succinylchlorids [On the reduction of succinyl chloride, in German]Justus Liebigs Ann Chem18741712589010.1002/jlac.18741710216Open DOISearch in Google Scholar
Britt GC, McCance-Katz EF. A brief overview of the clinical pharmacology of “club drugs”. Subst Use Misuse 2005;40:1189–201. doi: 10.1081/JA-200066730BrittGCMcCance-KatzEFA brief overview of the clinical pharmacology of “club drugs”Subst Use Misuse200540118920110.1081/JA-20006673016048813Open DOISearch in Google Scholar
Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y, Ofuji T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977;44:1014–7. doi: 10.1210/jcem-44-5-1014TakaharaJYunokiSYakushijiWYamauchiJYamaneYOfujiTStimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humansJ Clin Endocrinol Metab1977441014710.1210/jcem-44-5-1014Open DOISearch in Google Scholar
Busardò FP, Jones AW. Interpreting γ-hydroxybutyrate concentrations for clinical and forensic purposes. Clin Toxicol 2019;57:149–63.doi: 10.1080/15563650.2018.1519194BusardòFPJonesAWInterpreting γ-hydroxybutyrate concentrations for clinical and forensic purposesClin Toxicol 2019;57:149–6310.1080/15563650.2018.1519194Open DOISearch in Google Scholar
Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, Gallimberti L, Gessa GL, Ferrara SD. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993;45:353–6. doi: 10.1007/bf00265954PalatiniPTedeschiLFrisonGPadriniRZordanROrlandoRGallimbertiLGessaGLFerraraSDDose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteersEur J Clin Pharmacol199345353610.1007/bf00265954Open DOISearch in Google Scholar
Cuypers E, Flanagan RJ. The interpretation of hair analysis for drugs and drug metabolites. Clin Toxicol 2018;56:90–100. doi: 10.1080/15563650.2017.1379603CuypersEFlanaganRJThe interpretation of hair analysis for drugs and drug metabolitesClin Toxicol2018569010010.1080/15563650.2017.1379603Open DOISearch in Google Scholar
Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta 2006;370:17–49. doi: 10.1016/j.cca.2006.02.019PragstFBalikovaMAState of the art in hair analysis for detection of drug and alcohol abuseClin Chim Acta2006370174910.1016/j.cca.2006.02.019Open DOISearch in Google Scholar
Ferrara SD, Tedeschi L, Frison G, Orlando R, Mazzo M, Zordan R, Padrini R, Palatini P. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. Eur J Clin Pharmacol 1996;50:305–10. doi: 10.1007/s002280050113FerraraSDTedeschiLFrisonGOrlandoRMazzoMZordanRPadriniRPalatiniPEffect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acidEur J Clin Pharmacol1996503051010.1007/s002280050113Open DOISearch in Google Scholar
Thai D, Dyer JE, Jacob P, Haller CA. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 2007;81:178–84. doi: 10.1038/sj.clpt.6100037ThaiDDyerJEJacobPHallerCAClinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteersClin Pharmacol Ther2007811788410.1038/sj.clpt.6100037Open DOISearch in Google Scholar
Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980;6:93–9. PMID: 7449723HoesMJVreeTBGuelenPJGamma-hydroxybutyric acid as hypnoticClinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man Encephale19806939PMID: 7449723Search in Google Scholar
Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroencephalogr Clin Neurophysiol 1966;20:506–12. doi: 10.1016/0013-4694(66)90107-6MetcalfDREmdeRNStripeJTAn EEG-behavioral study of sodium hydroxybutyrate in humansElectroencephalogr Clin Neurophysiol1966205061210.1016/0013-4694(66)90107-6Open DOISearch in Google Scholar
van Amsterdam JGC, Brunt TM, McMaster MTB, Niesink RJM. Possible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev 2012;36:1217–27. doi: 10.1016/j.neubiorev.2012.02.002vanAmsterdam JGCBruntTMMcMasterMTBNiesinkRJMPossible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdoseNeurosci Biobehav Rev20123612172710.1016/j.neubiorev.2012.02.00222342779Open DOISearch in Google Scholar
Morse BL, Morris ME. Toxicokinetics/toxicodynamics of γ-hydroxybutyrate-ethanol intoxication: Evaluation of potential treatment strategies. J Pharmacol Exp Ther 2013;346:504–13. doi: 10.1124/jpet.113.206250MorseBLMorrisMEToxicokinetics/toxicodynamics of γ-hydroxybutyrate-ethanol intoxication: Evaluation of potential treatment strategiesJ Pharmacol Exp Ther20133465041310.1124/jpet.113.206250387677923814094Open DOISearch in Google Scholar
Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998;31:716–22. doi: 10.1016/S0196-0644(98)70230-6ChinRLSporerKACullisonBDyerJEWuTDClinical course of gamma-hydroxybutyrate overdoseAnn Emerg Med1998317162210.1016/S0196-0644(98)70230-6Open DOISearch in Google Scholar
Ortmann LA, Jaeger MW, James LP, Schexnayder SM. Coma in a 20-month-old child from an ingestion of a toy containing 1,4-butanediol, a precursor of γ-hydroxybutyrate. Pediatr Emerg Car e 2009;25:758–60. doi: 10.1097/ PEC.0b013e3181bec93bOrtmannLAJaegerMWJamesLPSchexnayderSMComa in a 20-month-old child from an ingestion of a toy containing 1,4-butanediol, a precursor of γ-hydroxybutyratePediatr Emerg Car e2009257586010.1097/PEC.0b013e3181bec93bOpen DOISearch in Google Scholar
Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000;19:47–50. doi: 10.1016/s0736-4679(00)00188-8IngelsMRanganCBellezzoJClarkRFComa and respiratory depression following the ingestion of GHB and its precursors: three casesJ Emerg Med200019475010.1016/s0736-4679(00)00188-8Open DOISearch in Google Scholar
Williams H, Taylor R, Roberts M. Gamma-hydroxybutyrate (GHB): a new drug of misuse. Ir Med J 1998;91:56–7. PMID: 9617031WilliamsHTaylorRRobertsMGamma-hydroxybutyrate (GHB): a new drug of misuseIr Med J199891567PMID: 9617031Search in Google Scholar
Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992;156:380–4. PMCID: PMC1003276ChinMYKreutzerRADyerJEAcute poisoning from gamma-hydroxybutyrate in CaliforniaWest J Med19921563804PMCID: PMC1003276Search in Google Scholar
Elian AA. Determination of endogenous gamma-hydroxybutyric acid (GHB) levels in antemortem urine and blood. Forensic Sci Int 2002;128:120–2. doi: 10.1016/S0379-0738(02)00183-4ElianAADetermination of endogenous gamma-hydroxybutyric acid (GHB) levels in antemortem urine and bloodForensic Sci Int2002128120210.1016/S0379-0738(02)00183-4Open DOISearch in Google Scholar
LeBeau MA, Christenson RH, Levine B, Darwin WD, Huestis MA. Intra- and interindividuai variations in urinary concentrations of endogenous gamma-hydroxybutyrate. J Anal Toxicol 2002;26:340–6. doi: 10.1093/jat/26.6.340LeBeauMAChristensonRHLevineBDarwinWDHuestisMAIntra- and interindividuai variations in urinary concentrations of endogenous gamma-hydroxybutyrateJ Anal Toxicol200226340610.1093/jat/26.6.340Open DOISearch in Google Scholar
Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int 2003;133:9–16. doi: 10.1016/s0379-0738(03)00043-4ElliottSPGamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous productionForensic Sci Int200313391610.1016/s0379-0738(03)00043-4Open DOISearch in Google Scholar
Yeatman DT, Reid K. A study of urinary endogenous gamma-hydroxybutyrate (GHB) levels. J Anal Toxicol 2003;27:40–2. doi: 10.1093/jat/27.1.40YeatmanDTReidKA study of urinary endogenous gamma-hydroxybutyrate (GHB) levelsJ Anal Toxicol20032740210.1093/jat/27.1.4012587682Open DOISearch in Google Scholar
Sørensen LK, Hasselstrøm JB. A hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry method for the simultaneous determination of γ-hydroxybutyrate and its precursors in forensic whole blood. Forensic Sci Int 2012;222:352–9. doi: 10.1016/j.forsciint.2012.07.017SørensenLKHasselstrømJBA hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry method for the simultaneous determination of γ-hydroxybutyrate and its precursors in forensic whole bloodForensic Sci Int2012222352910.1016/j.forsciint.2012.07.01722917943Open DOISearch in Google Scholar
Elian AA, Hackett J. Anion exchange SPE and liquid chromatography-tandem mass spectrometry in GHB analysis. J Chromatogr B 2011;879:3752–8. doi: 10.1016/j. jchromb.2011.09.018ElianAAHackettJAnion exchange SPE and liquid chromatography-tandem mass spectrometry in GHB analysisJ Chromatogr B20118793752810.1016/j.jchromb.2011.09.01822055831Open DOISearch in Google Scholar
Dahl SR, Olsen KM, Strand DH. Determination of γ-hydroxybutyrate (GHB), β-hydroxybutyrate (BHB), pregabalin, 1,4-butane-diol (1,4BD) and γ-butyrolactone (GBL) in whole blood and urine samples by UPLC-MSMS. J Chromatogr B 2012;885–886:37–42. doi: 10.1016/j.jchromb.2011.12.009DahlSROlsenKMStrandDHDetermination of γ-hydroxybutyrate (GHB), β-hydroxybutyrate (BHB), pregabalin, 1,4-butane-diol (1,4BD) and γ-butyrolactone (GBL) in whole blood and urine samples by UPLC-MSMSJ Chromatogr B2012885–886374210.1016/j.jchromb.2011.12.00922226469Open DOISearch in Google Scholar
Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of γ-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 1997;224:71–4. doi: 10.1016/s0304-3940(97)13470-xFeigenbaumJJHowardSGNaloxone reverses the inhibitory effect of γ-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis studyNeurosci Lett199722471410.1016/s0304-3940(97)13470-xOpen DOISearch in Google Scholar
Devoto P, Colombo G, Cappai F, Gessa GL. Naloxone antagonizes ethanol- but not α-hydroxybutyrate-induced sleep in mice. Eur J Pharmacol 1994;252:321–4. doi: 10.1016/0014-2999(94)90179-1DevotoPColomboGCappaiFGessaGLNaloxone antagonizes ethanol- but not α-hydroxybutyrate-induced sleep in miceEur J Pharmacol1994252321410.1016/0014-2999(94)90179-1Open DOISearch in Google Scholar
Thomas G, Bonner S, Gascoigne A. Coma induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): a case report. BMJ 1997;314:35–6. doi: 10.1136/bmj.314.7073.35ThomasGBonnerSGascoigneAComa induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): a case reportBMJ199731435610.1136/bmj.314.7073.35Open DOISearch in Google Scholar
Lee DC, Satz WA, Dougherty T, Greene T. An investigation of flumazenil to antagonize gamma-hydroxybutyrate intoxication in a murine model. J Med Toxicol 2006;2:68–70. doi: 10.1007/bf03161174LeeDCSatzWADoughertyTGreeneTAn investigation of flumazenil to antagonize gamma-hydroxybutyrate intoxication in a murine modelJ Med Toxicol20062687010.1007/bf03161174Open DOISearch in Google Scholar
Schmidt-Mutter C, Pain L, Sandner G, Gobaille S, Maitre M. The anxiolytic effect of γ-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil. Eur J Pharmacol 1998;342:21–7. doi: 10.1016/s0014-2999(97)01503-3Schmidt-MutterCPainLSandnerGGobailleSMaitreMThe anxiolytic effect of γ-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenilEur J Pharmacol199834221710.1016/s0014-2999(97)01503-3Open DOISearch in Google Scholar
Mahr G, Bishop CL, Orringer DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001;42:439–40. doi: 10.1176/appi.psy.42.5.439MahrGBishopCLOrringerDJProlonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abusePsychosomatics2001424394010.1176/appi.psy.42.5.439Open DOISearch in Google Scholar
van Noorden MS, van Dongen LCAM, Zitman FG, Vergouwen TA. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry 2009;31:394–6.doi:10.1016/j.genhosppsych.2008.11.001vanNoorden MSvanDongen LCAMZitmanFGVergouwenTAGamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-knownGen Hosp Psychiatry 2009;31:394–610.1016/j.genhosppsych.2008.11.001Open DOISearch in Google Scholar
Miglani JS, Kim KY, Chahil R. Gamma-hydroxy butyrate withdrawal delirium: a case report. Gen Hosp Psychiatry 2000;22:213–5. doi: 10.1016/s0163-8343(00)00071-2MiglaniJSKimKYChahilRGamma-hydroxy butyrate withdrawal delirium: a case reportGen Hosp Psychiatry200022213510.1016/s0163-8343(00)00071-2Open DOISearch in Google Scholar
Hutto B, Fairchild A, Bright R. γ-Hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry 2000;157:1706. doi: 10.1176/appi.ajp.157.10.1706HuttoBFairchildABrightRγ-Hydroxybutyrate withdrawal and chloral hydrateAm J Psychiatry2000157170610.1176/appi.ajp.157.10.1706Open DOISearch in Google Scholar
Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000;18:65–70. doi: 10.1016/s0736-4679(99)00163-8CraigKGomezHFMcManusJLBaniaTCSevere gamma-hydroxybutyrate withdrawal: a case report and literature reviewJ Emerg Med200018657010.1016/s0736-4679(99)00163-8Open DOISearch in Google Scholar
Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005;19:195–204. doi: 10.1177/0269881105049041GonzalezANuttDJGamma hydroxy butyrate abuse and dependencyJ Psychopharmacol20051919520410.1177/026988110504904115871147Open DOISearch in Google Scholar
Hernandez M, McDaniel CH, Costanza CD, Hernandez OJ. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am J Drug Alcohol Abuse 1998;24:179–83. doi: 10.3109/00952999809001706HernandezMMcDanielCHCostanzaCDHernandezOJGHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acidAm J Drug Alcohol Abuse1998241798310.3109/009529998090017069513637Open DOISearch in Google Scholar
McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75:3–9. doi: 10.1016/j.drugalcdep.2004.01.012McDonoughMKennedyNGlasperABearnJClinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a reviewDrug Alcohol Depend2004753910.1016/j.drugalcdep.2004.01.01215225884Open DOISearch in Google Scholar
World Health Organization (WHO). γ-Butyrolactone (GBL). Who Expert Committee on Drug Dependence. WHO Technical Report Series 973. Geneva: WHO; 2012. p. 14–5.World Health Organization (WHO). γ-Butyrolactone (GBL). Who Expert Committee on Drug Dependence. WHO Technical Report Series 973GenevaWHO2012p14–5Search in Google Scholar
Koek W, Mercer SL, Coop A. Cataleptic effects of γ-hydroxybutyrate (GHB), its precursor γ-butyrolactone (GBL), and GABAB receptor agonists in mice: Differential antagonism by the GABAB receptor antagonist CGP35348. Psychopharmacology (Berl) 2007;192:407–14. doi: 10.1007/s00213-007-0718-yKoekWMercerSLCoopACataleptic effects of γ-hydroxybutyrate (GHB), its precursor γ-butyrolactone (GBL), and GABAB receptor agonists in mice: Differential antagonism by the GABAB receptor antagonist CGP35348Psychopharmacology (Berl)20071924071410.1007/s00213-007-0718-y17277933Open DOISearch in Google Scholar
Carai MAM, Lobina C, Maccioni P, Cabras C, Colombo G, Gessa GL. γ-Aminobutyric acidB (GABAB-receptor mediation of different in vivo effects of γ-butyrolactone. J Pharmacol Sci 2008;106:199–207. doi: 10.1254/jphs. FP0071487CaraiMAMLobinaCMaccioniPCabrasCColomboGGessaGLγ-Aminobutyric acidB (GABAB-receptor mediation of different in vivo effects of γ-butyrolactoneJ Pharmacol Sci200810619920710.1254/jphs.FP007148718270475Open DOISearch in Google Scholar
Goodwin AK, Brown PR, Jansen EEW, Jakobs C, Gibson KM, Weerts EM. Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psychopharmacology (Berl) 2009;204:465–76. doi: 10.1007/s00213-009-1477-8GoodwinAKBrownPRJansenEEWJakobsCGibsonKMWeertsEMBehavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboonsPsychopharmacology (Berl)20092044657610.1007/s00213-009-1477-8268263519198808Open DOISearch in Google Scholar
Busardò FP, Pichini S, Zaami S, Pacifici R, Kintz P. Hair testing of GHB: An everlasting issue in forensic toxicology. Clin Chem Lab Med 2018;56:198–208. doi: 10.1515/cclm-2017-0397BusardòFPPichiniSZaamiSPacificiRKintzPHair testing of GHB: An everlasting issue in forensic toxicologyClin Chem Lab Med20185619820810.1515/cclm-2017-039728763296Open DOISearch in Google Scholar
Busardò FP, Kyriakou C, Cipolloni L, Zaami S, Frati P. From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate. Curr Neuropharmacol. 2016;14:17-27. doi: 10.2174/1570159x13666150407225902BusardòFPKyriakouCCipolloniLZaamiSFratiPFrom Clinical Application to Cognitive Enhancement: The Example of MethylphenidateCurr Neuropharmacol201614172710.2174/1570159x13666150407225902478728026813119Open DOISearch in Google Scholar
Kyriakou C, Pellegrini M, García-Algar O, Marinelli E, Zaami S. Recent trends in analytical methods to determine new psychoactive substances in hair. Curr Neuropharmacol 2016;15:663–81. doi: 10.2174/1570159x15666161111112545KyriakouCPellegriniMGarcía-AlgarOMarinelliEZaamiSRecent trends in analytical methods to determine new psychoactive substances in hairCurr Neuropharmacol2016156638110.2174/1570159x15666161111112545577104427834146Open DOISearch in Google Scholar
Dornbierer DA, Kometer M, von Rotz R, Studerus E, Gertsch J, Salomé Gachet M, Vollenweider FX, Seifritza E, Bosch OG, Quednow BB. Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring. European Neuropsychopharmacology 2019;29:539–48. doi: 10.1016/j.euroneuro.2019.02.004DornbiererDAKometerMvonRotz RStuderusEGertschJSaloméGachet MVollenweiderFXSeifritzaEBoschOGQuednowBBEffects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoringEuropean Neuropsychopharmacology2019295394810.1016/j.euroneuro.2019.02.00430824339Open DOISearch in Google Scholar